Moomoo AI 已提取核心訊息
In8bio, Inc., a biotechnology company incorporated in Delaware and based in New York, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of securities offering. The filing, dated December 28, 2023, reports that the company has successfully raised $14,425,013 USD through the sale of equity and securities with options or warrants. The offering, which commenced on December 13, 2023, did not last more than a year and has been completed with the total offering amount sold. The company has claimed an exemption under Rule 506(b) and has not disclosed the use of proceeds for payments to any executive officers, directors, or promoters. The filing also notes that sales commissions totaling $643,470 USD were paid in connection with the offering. The company's executive officers and directors, including Chief Financial Officer Patrick McCall, are listed in the filing. In8bio has not made this offering in connection with a business combination transaction and has not accepted any investment from non-accredited investors.
In8bio, Inc., a biotechnology company incorporated in Delaware and based in New York, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of securities offering. The filing, dated December 28, 2023, reports that the company has successfully raised $14,425,013 USD through the sale of equity and securities with options or warrants. The offering, which commenced on December 13, 2023, did not last more than a year and has been completed with the total offering amount sold. The company has claimed an exemption under Rule 506(b) and has not disclosed the use of proceeds for payments to any executive officers, directors, or promoters. The filing also notes that sales commissions totaling $643,470 USD were paid in connection with the offering. The company's executive officers and directors, including Chief Financial Officer Patrick McCall, are listed in the filing. In8bio has not made this offering in connection with a business combination transaction and has not accepted any investment from non-accredited investors.
in8bio, Inc. 是一家在特拉華州註冊成立、總部位於紐約的生物技術公司，已向美國證券交易委員會提交了D表格的證券豁免發行通知，表明了新的證券發行通知。該文件日期爲2023年12月28日，報告稱，該公司通過出售帶有期權或認股權證的股票和證券，成功籌集了14,425,013美元。此次發行於2023年12月13日開始，持續時間不超過一年，並已完成發行總額。該公司已根據第506（b）條申請豁免，並且沒有透露所得款項用於向任何執行官、董事或發起人付款的用途。該文件還指出，與本次發行相關的銷售佣金總額爲643,470美元。文件中列出了該公司的執行官和董事，包括首席財務官帕特里克·麥考爾。In8bio沒有提供與業務合併交易相關的本次發行，也沒有接受來自未經認證的投資者的任何投資。
in8bio, Inc. 是一家在特拉華州註冊成立、總部位於紐約的生物技術公司，已向美國證券交易委員會提交了D表格的證券豁免發行通知，表明了新的證券發行通知。該文件日期爲2023年12月28日，報告稱，該公司通過出售帶有期權或認股權證的股票和證券，成功籌集了14,425,013美元。此次發行於2023年12月13日開始，持續時間不超過一年，並已完成發行總額。該公司已根據第506（b）條申請豁免，並且沒有透露所得款項用於向任何執行官、董事或發起人付款的用途。該文件還指出，與本次發行相關的銷售佣金總額爲643,470美元。文件中列出了該公司的執行官和董事，包括首席財務官帕特里克·麥考爾。In8bio沒有提供與業務合併交易相關的本次發行，也沒有接受來自未經認證的投資者的任何投資。
有用
沒用